Adrenorphin is widely distributed throughout the mammalian brain. It has strong opioid activity, can be used as an effective agonist of μ opioid receptors, and has analgesic and respiratory depression effects. Ki is 12 nM.
CAT No: R1816
CAS No: 88377-68-8
Synonyms/Alias: adrenorphin;Metorphamide;88377-68-8;HY-P1087;MFCD00065523;Tyr-Gly-Gly-Phe-Met-Arg-Arg-Val-NH2;DA-65420;MS-31834;H-Tyr-Gly-Gly-Phe-Met-Arg-Arg-Val-NH2;CS-0027637;Metorphamide; Tyr-Gly-Gly-Phe-Met-Arg-Arg-Val-NH2;(S)-N-((S)-1-amino-3-methyl-1-oxobutan-2-yl)-2-((2S,5S,8S,17S)-17-amino-8-benzyl-2-(3-guanidinopropyl)-18-(4-hydroxyphenyl)-5-(2-(methylthio)ethyl)-4,7,10,13,16-pentaoxo-3,6,9,12,15-pentaazaoctadecanamido)-5-guanidinopentanamide;
Quick InquiryCustom Peptide SynthesisPeptide Library Construction and Screening
Powerful screening tools in biological and chemical research
M.F/Formula | C44H69N15O9S |
M.W/Mr. | 984.2 |
Sequence | One Letter Code:YGGFMRRV Three Letter Code:H-Tyr-Gly-Gly-Phe-Met-Arg-Arg-Val-NH2 |
Appearance | Powder |
Purity | > 95% |
Long-term Storage Conditions | DMSO : 50 mg/mL (50.80 mM; Need ultrasonic) |
Shipping Condition | Ship with RT , or blue ice upon request |
InChI | InChI=1S/C44H69N15O9S/c1-25(2)36(37(46)63)59-41(67)31(12-8-19-52-44(49)50)57-39(65)30(11-7-18-51-43(47)48)56-40(66)32(17-20-69-3)58-42(68)33(22-26-9-5-4-6-10-26)55-35(62)24-53-34(61)23-54-38(64)29(45)21-27-13-15-28(60)16-14-27/h4-6,9-10,13-16,25,29-33,36,60H,7-8,11-12,17-24,45H2,1-3H3,(H2,46,63)(H,53,61)(H,54,64)(H,55,62)(H,56,66)(H,57,65)(H,58,68)(H,59,67)(H4,47,48,51)(H4,49,50,52)/t29-,30-,31-,32-,33-,36-/m0/s1 |
InChI Key | XJOQRTJDYAHKPY-MWSMAVIUSA-N |
Canonical SMILES | CC(C)C(C(=O)N)NC(=O)C(CCCN=C(N)N)NC(=O)C(CCCN=C(N)N)NC(=O)C(CCSC)NC(=O)C(CC1=CC=CC=C1)NC(=O)CNC(=O)CNC(=O)C(CC2=CC=C(C=C2)O)N |
1. The spatiotemporal control of signalling and trafficking of the GLP-1R
2. TMEM16F and dynamins control expansive plasma membrane reservoirs
3. Urinary Metabolites Associated with Blood Pressure on a Low-or High-Sodium Die
4. Autoinhibition and phosphorylation-induced activation of phospholipase C-γ isozymes
5. C-Peptide replacement therapy and sensory nerve function in type 1 diabetic neuropathy
If you have any peptide synthesis requirement in mind, please do not hesitate to contact us at info@creative-peptides.com. We will endeavor to provide highly satisfying products and services.
USA
Address: SUITE 115, 17 Ramsey Road, Shirley, NY 11967, USA
Tel: 1-631-624-4882
Fax: 1-631-614-7828
Email: info@creative-peptides.com
Germany
Address: Industriepark Höchst, Gebäude G830
65929 Frankfurt am Main
Email: info@creative-peptides.com